astragaloside a has been researched along with Diabetes Mellitus in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, Z; Gao, R; Qu, H; Yang, Q; Yin, Y | 1 |
| Fan, H; Fan, Y; Huang, L; Li, P; Liu, Q; Zhou, Y | 1 |
| Hu, Y; Hu, Z; Liu, W; Pan, C; Tang, W | 1 |
| Li, L; Li, Y; Luo, Y; Meng, X; Pan, G; Zhang, B; Zhang, H; Zhang, Y | 1 |
| Gao, Y; Su, X; Xue, T; Zhang, N | 1 |
| Cui, J; Gao, Y; He, J; Li, Y; Shan, X; Shi, Y; Wang, T; Xin, J; Zhu, Z | 1 |
| Fang, ZH; Lin, YX; Shen, GM; Wang, TT; You, LZ; Zhao, JD | 1 |
3 review(s) available for astragaloside a and Diabetes Mellitus
| Article | Year |
|---|---|
The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications.
Topics: Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus; Humans; Inflammation; Saponins | 2023 |
The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Humans; Kidney; Saponins; Triterpenes | 2023 |
[Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects].
Topics: Animals; Astragalus propinquus; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Saponins; Triterpenes | 2017 |
4 other study(ies) available for astragaloside a and Diabetes Mellitus
| Article | Year |
|---|---|
Astragaloside IV alleviates Schwann cell injury in diabetic peripheral neuropathy by regulating microRNA-155-mediated autophagy.
Topics: Animals; Apoptosis; Autophagy; Diabetes Mellitus; Diabetic Neuropathies; MicroRNAs; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Saponins; Schwann Cells; Triterpenes | 2021 |
Mitogen-activating protein kinase kinase kinase kinase-3, inhibited by Astragaloside IV through H3 lysine 4 monomethylation, promotes the progression of diabetic nephropathy by inducing apoptosis.
Topics: Animals; Apoptosis; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Female; Lysine; Male; Mice; Mitogens; Protein Kinases; Protein Serine-Threonine Kinases; Rats, Sprague-Dawley; Saponins; Triterpenes | 2022 |
Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
Topics: Animals; Chemokine CX3CL1; Diabetes Mellitus; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Fibrosis; Hyperglycemia; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Saponins; Signal Transduction; Triterpenes | 2022 |
Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Inflammasomes; Mice; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Podocytes; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2023 |